Projects

These projects are based on our longstanding interest in the cardioprotective effects of adiponectin and the mechanisms via which adiponectin acts. 

These studies investigate mechanisms relevant to development of heart failure in MetS patients with elevated iron levels or who experience IRI. 

Examining cellular consequences of excess iron on skeletal muscle. The work is based on the hypothesis that excess labile iron regulates cellular stress related processes in skeletal muscle which have important metabolic consequences.

This project is focused on the analysis of extracellular vesicle cargo composition in patients with metabolic syndrome, and the functional biological significance of these extracellular vesicles tested in cellular models. This is the first project launched by the newly established Thai-Canada Research Laboratory, based at Srinakharinwirot University and developed with support from the Embassy of Canada in Thailand and for which York University is the inaugural partner. This initial research collaboration will pave the way for strong future academic research collaborations between Thailand and Canada.

We are conducting pre-clinical testing on a new drug, designed to mimic adiponectin. Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical company developing first-in-class therapeutic peptides that uniquely target adiponectin signaling pathways. Adiponectin has multiple beneficial actions, including anti-inflammatory, anti-fibrotic, cell regenerative, and beneficial metabolic properties that provides development opportunities in multiple diseases. Allysta has also developed an extended release formulation of the lead drug ALY688 (ALY688-ER) ideally suited for systemic administration and Phase-I clinical trials are expected to begin soon.

Lab2Market Program and launch of our spin-off company www.adevbio.com focused on adiponectin therapeutics harnessing the power of extracellular vesicles.